Condition (MeSH)
Respiratory Aspiration
ClinicalTrials.gov lists 973 trials for Respiratory Aspiration or a narrower condition beneath it. AstraZeneca has the most among industry and government lead sponsors, with 22.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
952 of the 973 trials are tagged with Respiratory Aspiration itself; the rest are tagged with a narrower condition beneath it.
When did Respiratory Aspiration trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 3 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Unknown)
Top of scale: 77
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 69 |
| 2025 | 77 |
| 2024 | 62 |
| 2023 | 66 |
| 2022 | 53 |
| 2021 | 61 |
| 2020 | 53 |
| 2019 | 55 |
| 2018 | 49 |
| 2017 | 40 |
Showing 10 of 30 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 86 trials starting in 2026 and about 77 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 24 months from start to primary completion across 71 trials still running at the 2026-10-09 snapshot; registered median of 12 months across 620 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Respiratory Aspiration trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 63 |
| Phase 1/2 | 19 |
| Phase 2 | 46 |
| Phase 2/3 | 6 |
| Phase 3 | 36 |
| Phase 4 | 46 |
| Not applicable | 517 |
| Observational | 238 |
| Expanded access | 1 |
| Unknown | 1 |
How many Respiratory Aspiration trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 45 |
| Recruiting | 97 |
| Enrolling by invitation | 17 |
| Active, not recruiting | 16 |
| Completed | 591 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Respiratory Aspiration trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| AstraZeneca | 22 |
| GlaxoSmithKline | 8 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 7 |
| Bayer | 6 |
| Aeris Therapeutics | 5 |
Which drugs are being tested for Respiratory Aspiration? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| PROPOFOL | 11 |
| Pentamidine Isethionate | 6 |
| DEXMEDETOMIDINE | 5 |
| Desflurane | 5 |
| FENTANYL | 5 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 1% Sevoflurane | 16 |
| Pressure Support Ventilation | 7 |
| Tiotropium bromide via (Spiriva® Handihaler®) | 6 |
| Control (placebo) group | 5 |
| mechanical ventilation (MV) | 5 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Respiratory Aspiration trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 83 | 3 |
| Respiratory failure | 23 | 2 |
| Chronic obstructive pulmonary disease | 20 | 1 |
| Acute respiratory failure | 17 | 2 |
| Dyspnoea | 16 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Respiratory Aspiration? (125)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Perioperative GLP1-RA management and risk of aspiration in patients with diabetes undergoing fast-track hip and knee arthroplasty. | Danish medical journal | 2025 | Yes |
| Impact of liberal preoperative clear fluid fasting regimens on the risk of pulmonary aspiration in children (EUROFAST): an international prospective cohort study. | British journal of anaesthesia | 2025 | Yes |
| Airway management and pulmonary aspiration during surgical interventions in pregnant women in the 2nd/3rd trimester and immediate postpartum - a retrospective study in a tertiary care university hospital. | BMC anesthesiology | 2024 | Yes |
| Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial. | JAMA | 2023 | Yes |
| Pulmonary Aspiration of Gastric Contents: A Closed Claims Analysis. | Anesthesiology | 2021 | Yes |
Showing 5 of 125 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.